A Meta-analysis of the Value of vWF in the Diagnosis of Liver Cirrhosis with Portal Hypertension

Abstract Background and Aims: Studies have indicated that serum von Willebrand factor (vWF) has a positive correlation with hepatic venous pressure gradient. However, information on the value of vWF in the diagnosis of liver cirrhosis with portal hypertension has been lacking. The purpose of this meta-analysis was to assess the value of vWF in the diagnosis of liver cirrhosis with portal hypertension. Methods: Studies that analyzed the sensitivity, specificity, diagnostic odds ratio combined with likelihood ratios and test for heterogeneity of vWF in the diagnosis of liver cirrhosis with portal hypertension were found in the Cochrane Library, Ovid, VOS-SCI, CNKI, PubMed, Medline, EMBASE, CMB and Wanfang databases. In the end, the data was used to draw the summary receiver operating characteristic curve and to calculate the area under the curve. Results: Four studies involving 662 patients were analyzed. The results showed that serum vWF in liver cirrhosis with portal hypertension were significantly higher than in those without portal hypertension. Sensitivity combined was 0.823 (95% CI: 0.788, 0.855). Specificity combined was 0.782 (95% CI: 0.708, 0.845). +LR combined was 3.777 (95% CI: 2.794, 5.107). -LR combined was 0.221 (95% CI: 0.180, 0.272). Diagnostic odds ratio combined was 18.347 (95% CI: 11.725, 28.708). The area under the curve was 0.8896. Conclusions: Serum vWF can be used as an effective and feasible method for noninvasive diagnosis of liver cirrhosis with portal hypertension. However, further studies are still needed to evaluate the severity of liver cirrhosis with portal hypertension.

[1]  H. Tilg,et al.  Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III) , 2017, Wiener klinische Wochenschrift.

[2]  A. Ferlitsch,et al.  The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test , 2016, PloS one.

[3]  H. Gouya,et al.  Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging , 2016, European Radiology.

[4]  Qiang Zhu,et al.  von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis , 2015, Scandinavian journal of gastroenterology.

[5]  S. Nomura,et al.  An assessment of the characteristics and quality of diagnostic accuracy studies for positron emission tomography conducted in Japan: a systematic review , 2015, EJNMMI Research.

[6]  M. Trauner,et al.  Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis , 2012, Hepatology.

[7]  J. Bosch,et al.  Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension , 2011, Gut.

[8]  J. Talwalkar,et al.  A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[9]  Mercedes Fernandez,et al.  Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability , 2007, Hepatology.

[10]  Javier Zamora,et al.  Meta-DiSc : a software for meta-analysis of test accuracy data , 2015 .

[11]  R. Groszmann,et al.  The hepatic venous pressure gradient: Anything worth doing should be done right , 2004, Hepatology.

[12]  P. Mannucci,et al.  High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia , 1996, Hepatology.

[13]  A. Blann,et al.  von Willebrand factor and endothelial damage in essential hypertension. , 1993, Journal of human hypertension.